Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that
can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is
a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection
in subjects with advanced malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.